These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
4. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth. Ahmad G; El Sadda R; Botchkina G; Ojima I; Egan J; Amiji M Cancer Lett; 2017 Oct; 406():71-80. PubMed ID: 28803993 [TBL] [Abstract][Full Text] [Related]
5. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003 [TBL] [Abstract][Full Text] [Related]
6. Biodistribution and Pharmacokinetic Evaluations of a Novel Taxoid DHA-SBT-1214 in an Oil-in-Water Nanoemulsion Formulation in Naïve and Tumor-Bearing Mice. Ahmad G; Gattacecca F; El Sadda R; Botchkina G; Ojima I; Egan J; Amiji M Pharm Res; 2018 Mar; 35(4):91. PubMed ID: 29520477 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714 [TBL] [Abstract][Full Text] [Related]
8. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380 [TBL] [Abstract][Full Text] [Related]
9. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer. Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573 [TBL] [Abstract][Full Text] [Related]
10. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. Zheng NN; Zhou M; Sun F; Huai MX; Zhang Y; Qu CY; Shen F; Xu LM World J Gastroenterol; 2020 Jul; 26(26):3737-3749. PubMed ID: 32774054 [TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119 [TBL] [Abstract][Full Text] [Related]
13. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer. Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021 [TBL] [Abstract][Full Text] [Related]
15. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study. Zhang H; Chen J; Bai J; Zhang J; Huang S; Zeng L; Zhou P; Shen Q; Yin T Int J Surg; 2024 May; 110(5):2679-2691. PubMed ID: 38489548 [TBL] [Abstract][Full Text] [Related]